Kailikang® is the commercial brand name of Urinary Kallidinogenase for Injection, a human urinary kallidinogenase developed by Techpool Bio-Pharma Co., Ltd. It converts kininogen into kinin, dilates cerebral vessels, improves cerebral microcirculation, promotes angiogenesis and reduces neurological deficits in ischemic stroke.
Main Indications
For the treatment of mild to moderate acute thrombotic cerebral infarction, administered within 48 hours after symptom onset.
Clinical Research
A multicenter, randomized, double-blind, placebo-controlled Phase III trial in China confirmed that urinary kallidinogenase significantly improves neurological function and daily living ability in patients with acute ischemic stroke;
A large-scale Phase IV real-world study further validated its clinical benefit and safety profile in a broad population of acute cerebral infarction patients;
Clinical evidence demonstrated that early administration within 48 hours yields better therapeutic effects, with manageable adverse events under proper blood pressure monitoring.
Common Side Effects
Severe but important risks: Hypotension, intracranial hemorrhage, allergic shock;
Common mild adverse reactions: Headache, nausea, vomiting, fever, palpitation and flushing.
Approval Status in China
Original drug Kailikang® (Urinary Kallidinogenase for Injection, specification:0.15PNA unit per vial) was officially approved for marketing in China in 2005. It is currently a prescription biologic drug included in China’s category B medical insurance.
Buy Kailikang (Urinary Kallidinogenase for Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
